Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 12:21 PM
Ignite Modification Date:
2025-12-24 @ 12:21 PM
NCT ID:
NCT04289961
Eligibility Criteria:
Inclusion Criteria:
1. Patients with clinically-suspected or cytologically/histologically-proven Pancreatic Adenocarcinoma who have been referred for EUS-FNA. Patients who are already on treatment would also be eligible.
2. Patients who are 18 years or older.
3. Patients must be able to receive and understand verbal and written information regarding the study and give written informed consent.
4. Patients must be able to comply with trial requirements.
Exclusion Criteria:
1. Patients with other active malignancy would not be eligible with the exception of patients with squamous or basal cell carcinoma of the skin. An exception to this statement would be those patients with a known/suspected germ-line predisposition to suffer multiple malignancies, such as, but not limited to Hereditary Breast and Ovarian Cancer Syndrome (BRCA1/2), Lynch syndrome or multiple endocrine neoplasia (MEN) syndrome.
2. Patient with INR \>1.5 and/or platelets ≤50.
3. Patients with bleeding disorders.
4. Patients on anti-platelet or anti-coagulation treatment that cannot be temporarily discontinued around the procedure.
5. Patients who cannot give informed consent.
6. Patients with known Hepatitis C viral infection.
7. Patients with known Human Immunodeficiency Virus (HIV) infection.
8. If clinically judged by the investigator that the patient should not participate in the study.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Maximum Age:
80 Years
Study:
NCT04289961
Study Brief:
Protocol Section:
NCT04289961